The case for buying IFL at present over other similiar financial stocks is in the Value paradigm. The Growth paradigm would be a wager on the acquisitional potential of which IFL management has a fairly 50/50 shady history of. The management itself has a pretty aggressive and acquisitional disposition which I would argue historically is a net capital cost rather than of net capital output to shareholders. The margins are very small on IFL so what's needed for the company to surpass competition by leveraging of its huge capital base would be to improve margin and organic growth, which is why the management claims "synergies" are coming etc.
When we see large insider purchases of the stock (and admittedly, renato has purcahsed a bit), I think we may possibly have a sign of pending news of success of management's claimed "synergies" and a shift in momentum. I would argue there is weak (at best) upside momentum at present with IFL.
- Forums
- ASX - By Stock
- 1 to 2 month
IFL
insignia financial ltd
Add to My Watchlist
4.26%
!
$3.67

The case for buying IFL at present over other similiar financial...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$3.67 |
Change
0.150(4.26%) |
Mkt cap ! $2.461B |
Open | High | Low | Value | Volume |
$3.55 | $3.73 | $3.54 | $7.648M | 2.077M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 8965 | $3.67 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.72 | 693 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 8965 | 3.670 |
1 | 4097 | 3.660 |
2 | 4370 | 3.650 |
2 | 1900 | 3.600 |
2 | 25586 | 3.580 |
Price($) | Vol. | No. |
---|---|---|
3.720 | 693 | 2 |
3.730 | 34805 | 8 |
3.740 | 7097 | 2 |
3.750 | 16397 | 4 |
3.760 | 12243 | 3 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
IFL (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online